Lexicon Pharmaceuticals, Inc.
LXRXLexicon Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of new drugs, particularly in the areas of metabolic, autoimmune, and other serious diseases. Founded in 1995 and headquartered in The Woodlands, Texas, the company utilizes its proprietary gene knockout technology to identify potential drug targets and develop innovative therapies.
Company News
Lexicon Pharmaceuticals announced it will present clinical study data on sotagliflozin for Type 1 diabetes and pilavapadin for diabetic peripheral neuropathic pain at the American Diabetes Association 2026 Scientific Sessions in New Orleans. The company highlighted consistent A1c reductions with sotagliflozin across patient subgroups and pharmaco...
Hypertrophic cardiomyopathy (HCM) is a complex genetic heart condition causing thickening and stiffening of the heart muscle, leading to symptoms like fatigue, breathlessness, and chest discomfort. The condition can develop at any age and carries risks of serious complications including heart failure and sudden death. While no medications current...
Lexicon Pharmaceuticals announced results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP), supporting the selection of 10mg as the optimal dose for Phase 3 development. The drug achieved nominally significant reduction in average pain at Week 8 versus placebo with good tolerability. Additional precli...
Lexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company plans to use net proceeds for research and development of drug candidates...
Lexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company intends to use the net proceeds to fund research and development of drug ...
